Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK134612 vs Menactra in Healthy Subjects 10-25 Years
NCT00454909Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2007
- Primary completion
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoint: Number of Subjects With Serum Bactericidal Assay Using Human Complement Antibody Titers Greater Than or Equal to the Cut-off Value at Month 1. Started Apr 2007; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00454909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454909.